XERS Stock: Price, Earnings History and SEC Filings
Xeris Biopharma Holdings, Inc. (XERS) last traded at $10.71, down 0.37% on the latest session and up 12.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.00 against an analyst estimate of $0.02, a miss of 100.0%.
$10.71 -0.37%
1 month+12.03%
52-week high$11.42
52-week low$5.25
Volume1.55M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
XERS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $0.00 | $0.02 | -100.00% |
| Dec 2025 | Mar 2, 2026 | $0.06 | $0.03 | +100.00% |
| Sep 2025 | Nov 6, 2025 | $0.00 | $0.01 | -100.00% |
XERS beat the analyst EPS estimate in 1 of its last 3 reported quarters. Source: Nasdaq.
Latest SEC filings for XERS
SEC filing data is not available right now. You can search for XERS on SEC EDGAR.
XERS news
- Can Corcept Therapeutics Stock Rally 40% After This Dip?Oct 26, 2026 · trefis.com
- Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026Oct 22, 2026 · finance.yahoo.com
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. (XERS) is a US-listed public company on Nasdaq.